Hemant Kalia

Hemant Kalia

Auto-generated profile, based on publicly available information

Hemant Kalia

C.R.I.S.P Center for Research & Innovation in Spine & Pain, Rochester, NY, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
DSDawood Sayed
Dawood Sayed
JGJay Grider
Jay Grider
NSNatalie H. Strand
Natalie H. Strand
JHJonathan M Hagedorn
Jonathan M Hagedorn
SFSteven M. Falowski
Steven M. Falowski
TDTimothy R. Deer
Timothy R. Deer
Introduction: Painful lumbar spinal disorders represent a leading cause of disability in the US and worldwide. Interventional treatments for lumbar disorders are an effective treatment for the pain and disability from low back pain. Although many established and emerging interventional procedures are currently available, there exists a need for a defined guideline for their appropriateness, effectiveness, and safety. Objective: The ASPN Back Guideline was developed to provide clinicians the most comprehensive review of interventional treatments for lower back disorders. Clinicians should utilize the ASPN Back Guideline to evaluate the quality of the literature, safety, and efficacy of interventional treatments for lower back disorders. Methods: The American Society of Pain and Neuroscience (ASPN) identified an educational need for a comprehensive clinical guideline to provide evidence-based recommendations. Experts from the fields of Anesthesiology, Physiatry, Neurology, Neurosurgery, Radiology, and Pain Psychology developed the ASPN Back Guideline. The world literature in English was searched using Medline, EMBASE, Cochrane CENTRAL, BioMed Central, Web of Science, Google Scholar, PubMed, Current Contents Connect, Scopus, and meeting abstracts to identify and compile the evidence (per section) for back-related pain. Search words were selected based upon the section represented. Identified peer-reviewed literature was critiqued using United States Preventive Services Task Force (USPSTF) criteria and consensus points are presented. Results: After a comprehensive review and analysis of the available evidence, the ASPN Back Guideline group was able to rate the literature and provide therapy grades to each of the most commonly available interventional treatments for low back pain. Conclusion: The ASPN Back Guideline represents the first comprehensive analysis and grading of the existing and emerging interventional treatments available for low back pain. This will be a living document which will be periodically updated to the current standard of care based on the available evidence within peer-reviewed literature.

1 December 2023 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
NSNatalie H. Strand
Natalie H. Strand
RDRyan Steven D’Souza
Ryan Steven D’Souza
JKJay Karri
Jay Karri
HKHemant Kalia
Hemant Kalia
JWJackie Weisbein
Jackie Weisbein
AAAlaa Abd-Elsayed
Alaa Abd-Elsayed
Cannabinoids have recently gained a renewed interest due to their potential applicability to various medical conditions, specifically the management of chronic pain conditions. Unlike many other medications, medical cannabis is not associated with serious adverse events, and no overdose deaths have been reported. However, both safety and efficacy data for medical cannabis treatment of chronic, nonmalignant pain conditions are lacking. Therefore, representatives from the American Society of Pain and Neuroscience summarize the evidence, according to level and grade, for medical cannabis treatment of several different pain conditions. Treatment of cancer-related pain has prospective evidentiary support for the use of medical cannabis. Although 3 large and well-designed randomized controlled trials investigated cannabis treatment of cancer-related pain, the evidence yielded only a grade D recommendation. Neuropathic pain has been investigated in prospective studies, but a lack of high-quality evidence renders cannabis treatment for this indication a grade C recommendation. Both safety and efficacy data are lacking for use of medical cannabis to treat chronic nonmalignant pain conditions.

10 August 2022 in Pain Management
Verified
Journal Article
Closed access
HKHemant Kalia
Hemant Kalia
SPScott Pritzlaff
Scott Pritzlaff
ALAlice H Li
Alice H Li
EOEinar Ottestad
Einar Ottestad
AGAmitabh Gulati
Amitabh Gulati
KCKrishnan Chakravarthy
Krishnan Chakravarthy
Peripheral nerve stimulation is an established treatment modality for chronic neuropathic pain. Over the last decade, with the advent of innovative devices and delivery platforms, peripheral nerve ... Plain language summary Chronic nerve pain is a debilitating condition that can affect quality of life and functioning. The Nalu™ Neurostimulation System (Nalu Medical, CA, USA) provides long-term p...

1 June 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
BGBenjamin Gill
Benjamin Gill
CTCody Tidwell
Cody Tidwell
JHJonathan M Hagedorn
Jonathan M Hagedorn
AMAlexandra M Moreira
Alexandra M Moreira
MLMarco Lawandy
Marco Lawandy
TDTimothy R. Deer
Timothy R. Deer
Peripheral nerve stimulation (PNS) has evolved with various applications and durations of therapy. In recent years, extensive data has been developed on a 60-day treatment using a novel approach. Confusion exists on the use of a trial therapy, a permanent implant, and a 60-day duration treatment. The American Society of Pain and Neuroscience (ASPN) seeks to clarify the literature associated with this neuromodulation approach. A diverse group of experts was nominated to provide opinions and guidance based on evidence-graded assessment and clinical knowledge. This guidance is the first to specifically assess the clinical use of 60-day PNS and best medical practice.

1 May 2022 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
AAAlaa Abd-Elsayed
Alaa Abd-Elsayed
KFKenneth Fiala
Kenneth Fiala
JWJacqueline Weibstein
Jacqueline Weibstein
PCPooja Chopra
Pooja Chopra
CLChristopher Lam
Christopher Lam
TDTimothy Deer
Timothy Deer
Background: The use of intrathecal drug delivery for chronic and cancer pain medicine has been established for decades. However, optimization and utilization of this technique still lag behind other modalities for pain control. Some of this may be due to variability of surgical technique, medication usage and education. It is currently unclear on whether or not practitioners follow available algorithms for the use of intrathecal drug delivery systems. Methods: A survey developed by the American Society of Pain and Neuroscience (ASPN) was sent to its members via email using the cloud-based SurveyMonkey. After 30 days of being available, 159 different providers responded to the survey that consisted of 31 various multiple choice and free response questions. Each question was not required and the number of responses to each varied from 128 to 159. Results: Approximately 9% of those who successfully received and opened the email containing the survey responded, likely due to a small number of providers working with intrathecal drug delivery systems. Eighty-six of respondents practice medicine in the United States, and 87% of the respondents were attending physicians. A majority of respondents, approximately 74%, were board certified in pain medicine with 69% of respondents being train in anesthesiology. The first and second most used medications for intrathecal pump trial were morphine and fentanyl, respectively. Most respondents, approximately 96%, provide pre-operative/intra-operative antibiotics. The most common first-choice medication for implanted intrathecal pumps was also morphine with the most common implanted location being the abdomen. Conclusion: Interestingly, there is currently fairly substantial variation in the way providers utilize intrathecal pump delivery for both chronic and cancer pain. There is variation from the training background of the providers providing care, to the pre-implantation trial medications, to where the pump is implanted for each patient, to if the patient has the option to give themselves boluses once implanted. Further research is needed to elucidate current and best practices for intrathecal drug delivery system trials, implantations, and utilization.

15 December 2022 in Neuromodulation: Technology at the Neural Interface
Verified
Journal Article
Open access
HKHemant Kalia
Hemant Kalia
AAAlaa Abd-Elsayed
Alaa Abd-Elsayed
MMMark Malinowski
Mark Malinowski
ABAdam Burkey
Adam Burkey
RARany T. Abdallah
Rany T. Abdallah
KSKonstantin V. Slavin
Konstantin V. Slavin